Application of Nanotechnology in the Targeted Release of Anticancer Drugs in Ovarian Cancer Treatment
Abstract
As a pilot study to localize the MagNaGel nanoparticles in an orthotopic ovarian cancer mouse model by MRI, mice were injected intraperitoneally with ovarian cancer cells. Tumor growth was monitored by a 4.7T small animal MRI. Once tumor and ascites developed in the mice, cisplatin-loaded MagNagel particles with 10.0 nm IO core (no targeting ligand) were injected into the tail-vein of the cancer bearing mice. After set time periods, MRI was performed on the mice. Organs were harvested and drug levels determined. Relative nanoparticle distribution by MRI images were correlated with drug levels.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2006
- Accession Number
- ADA481815
Entities
People
- Colleen Feltmate
Organizations
- Brigham and Women's Hospital